Intravascular lithotripsy

Intravascular lithotripsy (IVL) helps interventional cardiologists break down heavily calcified plaques in the coronary and peripheral arteries prior to percutaneous coronary intervention. Shockwave Medical, now a part of Johnson & Johnson MedTech, got the ball rolling with its IVL therapies that use shockwave pulses to clear out the calcified plaques. Several other companies have now entered the space, working to develop their own IVL systems that can improve patient outcomes.

Medical device company raises $36M for emitter-free IVL platform
Boston-based Amplitude Vascular Systems is busy investigating the performance of its Pulse IVL platform in a wide variety of patient populations.
Experts in interventional cardiology, medical billing unite to discuss Shockwave Medical’s IVL technology
Intravascular lithotripsy has quickly emerged as one of healthcare’s most in-demand technologies. Now Shockwave Medical, part of Johnson & Johnson MedTech, is co-hosting a webinar designed to teach coding and billing specialists how to code appropriately for peripheral and coronary IVL procedures.
Boston Scientific enters IVL arms race with acquisition worth up to $664M
Boston Scientific has agreed to acquire Bolt Medical, a California-based medical device company focused on developing new intravascular lithotripsy technologies. The news comes less than one year after Johnson & Johnson acquired IVL pioneers Shockwave Medical for $13 billion.
Intravascular lithotripsy technology now a top priority for many healthcare companies
After the significant success of Shockwave Medical's IVL therapy to break up heavily calcified vessels without trauma, there are now several companies working on their own IVL devices.
Shockwave Medical’s IVL technology still safe, effective in patients with calcified nodules
Intravascular lithotripsy is still a safe and effective frontline preparation tool when PCI patients present with calcified nodules, a new two-year study confirmed. Researchers focused on stent expansion and luminal gain, among other key data points.

MedAxiom partners with Shockwave Medical to support ‘game-changing’ IVL technology

Shockwave Medical, now a part of Johnson & Johnson MedTech, continues to gain momentum among U.S. cardiologists. According to one MedAxiom executive, IVL "brings an important dimension to cardiovascular care for patients with calcified coronary and peripheral arterial disease."

Shockwave Medical, a Johnson & Johnson MedTech company, has officially launched its Shockwave E8 Peripheral IVL Catheter in the United States. Shockwave’s E8 catheter was designed specifically to treat patients with calcified femoropopliteal and below-the-knee (BTK) peripheral artery disease (PAD), including those diagnosed with complex chronic limb-threatening ischemia (CLTI).

Shockwave Medical launches new FDA-approved IVL catheter for PAD, CLTI

The new device, already cleared by the FDA, was designed to treat femoropopliteal and below-the-knee PAD.

The Shockwave Medical M5+ new peripheral intravascular lithotripsy (IVL) catheter cuts procedures times in half and was showed for the first time at the American College of Cardiology (ACC) 2022 meeting. It is designed to break up calcium in heavily calcified arteries to avoid the need for vessel trauma caused by high pressure angioplasty.

Intravascular lithotripsy, the technology at heart of $13B acquisition, linked to positive real-world data

The calcified plaque-shattering technology developed by Shockwave Medical continues to gain momentum. As more care teams start using IVL during PCI, researchers are paying close attention to its long-term impact on patient care.

It’s official: Johnson & Johnson completes $13B Shockwave Medical acquisition

The deal, first announced in April, has been finalized. Shockwave will now operate as a business unit within Johnson & Johnson MedTech, and its common stock is no longer trading on NASDAQ.

healthcare value value-based care money dollar

Johnson & Johnson to acquire Shockwave Medical for $13.1B

The rumors, it seems, were true. Once the deal is finalized, Shockwave Medical will operate as a business unit within Johnson & Johnson MedTech.

Video of Yousif Ahmad, MD, Yale, discussing IVL advances and increased reinbursements

Tracking key advances in intravascular lithotripsy

Yousif Ahmad, MD, spoke with Cardiovascular Business about the latest advances in IVL therapy, including new reimbursement changes for the technology.

Ziad Ali, MD, explaines the impact of coronary intravascular lithotripsy (IVL) use in nodular and eccentric calcium morphologies at TCT 2023. IVL was found to produce better outcomes than atherectomy or high pressure balloons. #TCT #TCT2023 #TCT23 #IVL

IVL is safe and effective across all calcium morphologies, new research confirms

Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

IVL gains higher level of reimbursement with one of biggest coding updates for PCI in decades

Intravascular lithotripsy therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1.

Intravascular lithotripsy

Medical device company raises $36M for emitter-free IVL platform

Experts in interventional cardiology, medical billing unite to discuss Shockwave Medical’s IVL technology

Boston Scientific enters IVL arms race with acquisition worth up to $664M

Intravascular lithotripsy technology now a top priority for many healthcare companies

Shockwave Medical’s IVL technology still safe, effective in patients with calcified nodules